Latest From Ipsen
Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options for patients with the rare bone disease.
The Scottish Medicines Consortium has OKd Keytruda, Decapeptyl, Yescarta and Skyrizi after patient access schemes were agreed that improved their cost-effectiveness. But Perjeta and Xtandi were rejected because the companies made no solid economic case for NHS funding.
- OTC, Consumer
- Specialty Pharmaceuticals
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Beaufour Ipsen
- Western Europe
- Parent & Subsidiaries
- Senior Management
David Meek, CEO
Aymeric le Chatelier, EVP, Fin. & CFO
Alexandre Lebeaut, MD, EVP, R&D & CSO
Ivana Magovcevic-Liebisch, EVP, CBO
- Contact Info
Phone: (33) 1 58 33 50 00
65 Quai George Gorse
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.